Unbiased Analysis of Today's Healthcare Issues
Typically, cost effectiveness analyses assume a constant price between drug approvals and loss of exclusivity. It is not clear, however, to what extent that assumption is valid, particularly after taking into account drug price discounts and rebates. A paper by Lin et al. (2024) uses 2007-2023 data on drug prices from SSR Health to answer…
An interesting study from Miquel Serra-Burriel et al. (2024) examines the impact of genericization on drug prices across 8 high-income countries (Australia, Canada, France, Germany, Japan, Switzerland, UK, and US). The authors used 2011-2020 IQVIA MIDAS data across 505 novel originator drugs. They found that: Price decreases were statistically significant over the 8 years after…
A Health Affairs Forefront paper by researchers Melanie Whittington, Peter Neumann, Joshua Cohen, and Jonathan Campbell makes a compelling case for incorporating drug price dynamics into cost effectiveness analysis. The first questions many people may have is ‘how do drug prices usually change over time?’ A drug’s net price often increases following launch and may…